NEW ORLEANS, November 8, 2004 – Results from a new study showed that coadministration of ZETIA® (ezetimibe) and fenofibrate significantly reduced LDL ("bad") cholesterol (LDL-C), non-high density ...
-- Achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each of placebo, ezetimibe 10 mg, and obicetrapib 10 mg monotherapy at ...
Results from the largest community-based clinical trial to date, involving more than 3000 patients, has shown that adding the cholesterol absorption inhibitor ezetimibe to ongoing stable statin ...
Please provide your email address to receive an email when new articles are posted on . Among adults with atherosclerotic CVD at very high risk, moderate-intensity statin plus ezetimibe combination ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results